Notice: Our website will be down for maintenance from June 13 - June 14.

First Patient Dosed in Phase 3 of Study in Patients with Severe Hemophilia A

The following is an excerpt from a press release from Sanofi Genzyme. Read the press release in its entirety here. Sanofi and SobiTM announced the first patient has been dosed in the Phase 3, open-label, interventional study of BIVV001 (rFVIIIFc-VWF-XTEN), in patients with severe hemophilia A (XTEND-1 study; NCT04161495). Sobi and Sanofi are development partners for […]

en_USEnglish